NEW YORK (GenomeWeb News) – Bernd Brust will shift out of his position as president of Life Technologies' commercial operations and will move into the role of president of Molecular Medicine, the company said in a filing yesterday with the US Securities and Exchange Commission.
Brust will be replaced as president of commercial operations at the beginning of the coming year by Nicolas Barthelemy, who has been leading the firm's Cell Systems division.
Life Technologies said that the Molecular Medicine business unit was formed to enable it to develop new strategies related to transitioning next-generation sequencing activities into clinical uses.
Martin Madaus has joined the board of directors for array maker Quanterix. Madaus recently was president, CEO and chairman for Millipore, and before that he was president and CEO at Roche Diagnostics and VP of business development for Roche Molecular Diagnostics. He currently is a director of the Massachusetts High Technology Council.
Mark Poznansky has taken on the post of CEO and president at the Ontario Genomics Institute, replacing the outgoing Christian Burks. Poznansky has been on OGI's board of directors for six years, and he served as chairman of the board for the past two years. He formerly was president and CEO of Viron Therapeutics, CEO and scientific director of the Robarts Research Institute in London, Ontario, and he founded the London Biotechnology Incubator. He also served as associate dean of medicine at the University of Alberta.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.